White Paper:

Oncology Outlook for 2022: Key Trends to Watch

2022 will be another busy year for the oncology market, full of more innovation, competitive disruption, and regulatory intrigue.  In this paper, our team explores five key trends for 2022:

  1. Significant broadening of the checkpoint inhibitor market
  2. Continued growth of radiopharmaceuticals
  3. Time in the spotlight for allogeneic therapies (in particular, natural-killer (NK)-cell directed therapies)
  4. Emergence of bi-specific antibodies as competitors to CAR-T therapies
  5. Growing regulatory scrutiny for oncology medicines

Along the way, we also offer some predictions for the year.

  • Hidden
  • This field is for validation purposes and should be left unchanged.